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Abstract
Current clinical practice is to prescribe to 95% of the planning target volume (PTV)
in 4D stereotactic body radiotherapy (SBRT) for lung. Frequently the PTV margin
has a very low physical density so that the internal target volume (ITV) receives an
unnecessarily high dose. This study investigates the alternative of prescribing to the
ITV while including the effects of positional uncertainties. Five patients were retro-
spectively studied with volumetric modulated arc therapy treatment plans. Five
plans were produced for each patient: a static plan prescribed to PTV D95%, three
probabilistic plans prescribed to ITV D95% and a static plan re‐prescribed to ITV
D95% after inverse planning. For the three probabilistic plans, the scatter kernel in
the dose calculation was convolved with a spatial uncertainty distribution consisting
of either a uniform distribution extending ±5 mm in the three orthogonal directions,
a distribution consisting of delta functions at ±5 mm, or a Gaussian distribution with
standard deviation 5 mm. Median ITV D50% is 23% higher than the prescribed dose
for static planning and only 10% higher than the prescribed dose for prescription to
the ITV. The choice of uncertainty distribution has less than 2% effect on the med-
ian ITV dose. Re‐prescribing a static plan and evaluating with a probabilistic dose
calculation results in a median ITV D95% which is 1.5% higher than when planning
probabilistically. This study shows that a robust probabilistic approach to planning
SBRT lung treatments results in the ITV receiving a dose closer to the intended pre-
scription. The exact form of the uncertainty distribution is not found to be critical.
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1 | INTRODUCTION
Stereotactic body radiotherapy (SBRT) has been shown to be an
effective treatment for small lung lesions, such as oligometastases.1,2
Typically, the gross tumor volume (GTV) is contoured on several
phases of a 4DCT scan, to yield an internal target volume (ITV)
encompassing the tumor throughout all breathing phases. A planning
target volume (PTV) consisting of the ITV plus 5 mm is then used
for treatment planning. Patients treated with SBRT on linear acceler-
ators are always imaged with cone‐beam CT (CBCT) immediately
before each treatment fraction, so that the spatial uncertainty of the
ITV is low. The PTV margin accounts for any residual positional
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uncertainty after registration of the CBCT to the planning CT,
together with any tumor delineation uncertainty.3
Treatment plans for this technique are invariably prescribed such
that 95% of the PTV receives the prescribed dose. The planning tar-
get margin often lies in low‐density lung material, so that the ITV
itself receives a much higher dose than the edge of the PTV.4,5 In an
ablative context, this is not in itself problematic, but clinical proto-
cols normally specify a maximum dose of around 140% of the pre-
scribed dose, which can then be difﬁcult to achieve. Furthermore,
normal tissue tolerances can be exceeded due to the excessively
high dose, creating difﬁculties in treatment planning and the risk of
normal tissue toxicity.
A more satisfactory approach is to prescribe directly to the ITV.
This volume is where the lesion itself is located throughout the
breathing cycle, and it has a density much closer to that of water
than the surrounding lung tissue. Prescribing to this volume there-
fore ensures that the lesion itself receives the correct dose, without
over‐prescription due to the inﬂuence of low‐density areas surround-
ing it. However, simply prescribing to a static ITV located centrally
within the PTV does not account for the spatial uncertainty in the
ITV. Instead, the expected dose to the ITV in the presence of uncer-
tainty should be used. This is carried out by convolving the delivered
dose with the probability distribution of ITV position.
Some understanding of this approach has already been acquired
in the ﬁeld of probabilistic planning.6,7 Furthermore, experience has
also been obtained in the context of breathing motion compensa-
tion, as discussed by Lujan et al.8 These authors also investigate
the outcome in the event that the actual probability density func-
tion (PDF) of position at the time of treatment does not match that
at the time of planning.9 Other authors have also made similar
investigations.10,11 These studies have convolved the static dose
distribution with the PDF of motion to obtain the expected dose
distribution under respiration (dose convolution). This is appropriate
because the motion or uncertainty distribution relates to a speciﬁc
local region of the patient, while the overall patient position
reﬂects no overall shift from planning. The primary dose calculation
occurs once for the ﬁxed geometry. An alternative is to convolve
the incident ﬂuence proﬁle of each beam with the appropriate
components of the PDF (ﬂuence convolution).12,13 This is computa-
tionally faster because the convolution is two‐dimensional rather
than three‐dimensional. Zhang et al.14 and Troﬁmov et al.15 have
extended this method to include nonrigid organ motion by evaluat-
ing the deformation during motion from multiple CT scans and
incorporating this information into the planning process. For han-
dling systematic setup errors, where the entire patient position var-
ies in relation to the treatment beam, the primary ﬂuence should
be calculated to reﬂect this overall shift. In this case, ﬂuence con-
volution is more appropriate, since the ﬂuence is modiﬁed before
ray‐tracing through the patient, and this modiﬁed ﬂuence is then
used in the calculation of the primary dose distribution (i.e., total
energy released per unit mass, TERMA). This study assumes that
the uncertainty distribution is localized to the ITV, so dose convolu-
tion is used. In practice, this is accomplished by convolving the
scatter kernel with the uncertainty kernel, and then using this com-
bined kernel for the dose calculation.
To a greater or lesser extent, it is possible to use the inverse
planning process to compensate for the effects of spatial uncer-
tainty.8,16 This is the general concept of robust and probabilistic
treatment planning,17–23 but this is not the primary goal of this
study. Instead, the aim is to determine the target dose when pre-
scribing directly to the ITV in the presence of spatial uncertainty.
Accordingly, convolved dose distributions are used throughout
inverse planning to avoid a sudden change in dose calculation at the
end of inverse planning, while predominantly conformal arc beams
are used to avoid compensation for the uncertainty.
This study aims to evaluate the dosimetric impact of prescribing
directly to the ITV in lung SBRT treatment plans. Several possible
distributions of ITV uncertainty are evaluated. Furthermore, to evalu-
ate the situation if a clinic simply prescribes to the ITV without tak-
ing into account spatial uncertainty, inverse planning is carried out
without the inclusion of spatial uncertainty, and then a ﬁnal dose
calculation is carried out with spatial uncertainty. It is expected that
the study will lead to improved consistency of dose to the ITV,
fewer compromises in the production of treatment plans, and avoid-
ance of unnecessary dose to critical structures.
2 | MATERIALS AND METHODS
Five lung SBRT patients were retrospectively studied. 4DCT scans
were acquired using a Brilliance Big Bore CT scanner (Philips, Cleve-
land, OH, USA). The GTV was outlined on the 0% and 50% phases
of the breathing cycle using Pinnacle3 (Philips, Madison, WI, USA),
and combined to form an ITV. The ITV was normally just the envel-
ope of the GTV volume on the 0% and 50% phases, but was
checked visually using a movie presentation of the breathing motion
to ensure that it encompassed the GTV at all times, and was edited
if necessary. The uncertainty in the ITV contour, estimated as
±2 mm, was included in the PTV margin in the case of static plan-
ning, and by probability distributions in the case of probabilistic plan-
ning based on the ITV. The uncertainty was principally composed of
(a) difﬁculty in assessing the extent of the gross tumor on the CT
scan, (b) assessment of the motion of the lesion at the various
phases of the breathing cycle, and (c) differences in breathing pat-
tern between planning and delivery. Due to the difﬁculty in assess-
ing the distribution of the uncertainty, its extent was taken to be of
equal magnitude in each of the cardinal directions. Contouring was
carried out in accord with UK stereotactic ablative radiotherapy
Guidelines.24 Median ITV volume was 4.3 cm3 (range 1.6–14.9 cm3).
A series of volumetric modulated arc therapy treatment plans
was constructed retrospectively for each patient using the Auto-
Beam (v5.8) in‐house treatment planning system. The isocenter was
positioned at the center of the ITV in all cases, and the treatment
beam consisted of a single gantry rotation from 178° to 182° with
4° control point spacing. The treatment plan was based on the 6 MV
ﬂattening ﬁlter‐free beam of a Versa HD accelerator (Elekta AB,
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Stockholm, Sweden).25 The control points were set into groups of
20° of gantry angle and the apertures in two out of every three
groups were constrained to conform to the PTV, with no penumbra
margin except 3 mm superiorly and inferiorly. In one out of every
three control point groups, the apertures were modulated, with a
minimum segment width of 15 mm. This hybrid approach was
intended to give a robust treatment plan with mostly conformal seg-
ments, but with the scope to include some modulation to improve
the dose distribution. The collimator angle was 2° in all cases.
The prescription used in this study was 54 Gy in 3 fractions, but
another fractionation scheme could equally have been used, with
similar results. For each patient, a static plan was produced, with no
spatial uncertainty distribution explicitly applied, and prescribed to
the PTV as normal, such that PTV D95% was 54 Gy in 3 fractions. In
addition, three further plans were produced, each with a distribution
of spatial uncertainty assigned to the ITV. The distributions were (a)
a uniform distribution of position from −5 mm to +5 mm in each of
the anterior‐posterior, left‐right and superior‐inferior directions, (b) a
distribution consisting of delta functions at ±5 mm in each of the
anterior‐posterior, left‐right and superior‐inferior directions, that is,
assuming the tumor spent all of its time at the extremities of posi-
tion, and (c) a Gaussian distribution with standard deviation 5 mm in
each of the cardinal directions. Note that this latter distribution was
somewhat wider than the other two due to its total width of around
two standard deviations (Fig. 1). Each of the plans with spatial
uncertainty was planned and prescribed to the ITV D95%. A ﬁnal
treatment plan for each patient investigated the effect of simply re‐
prescribing to the ITV D95%. This plan was constructed and calcu-
lated as a static plan, prescribed to the PTV. After inverse planning,
it was re‐prescribed to the ITV D95% and, without changing the mon-
itor units, recalculated using the Gaussian position distribution
described above. The purpose of this plan was to determine the
dose distribution in the presence of spatial uncertainty that resulted
in the event that the plan was created normally and then simply re‐
prescribed to the ITV.
Inverse planning was then accomplished using ﬂuence optimiza-
tion for the modulated control point groups, sequencing, and then
aperture optimization. Both the ﬂuence optimization and aperture
optimization stages used iterative least squares.26 For ﬂuence opti-
mization, the iterative least squares method adjusted the ﬂuence val-
ues, while for aperture optimization, it adjusted multileaf collimator
positions. Dose was calculated using a fast convolution dose calcula-
tion27 on a grid of 2 mm × 2 mm × 2 mm in resolution.
Convolution was carried out in patient space. In principle, for a
given point of interest, r, the total dose, D, was given by28:
D rð Þ ¼
Z
V0
ϕ r0ð Þs r  r0ð ÞdV0 (1)
where ϕ r0ð Þ was the primary ﬂuence at point r0, and s r  r0ð Þ was a
spatially invariant, polyenergetic scatter kernel. In this work, the total
F I G . 1 . The three distributions used to describe spatial uncertainty. (a) Uniform distribution, (b) delta function distribution and (c) Gaussian distribution.
BEDFORD ET AL. | 3
dose, Di(r) at a given point of interest, r, was calculated by a discrete
approximation:
Di rð Þ≈∑Jj¼1ϕ ri þ sj
 
σj; i ¼ 1 . . . I: (2)
where sj was the position of the jth scatter point relative to the point
of interest, and σj was the corresponding scatter contribution. For the
discrete scatter kernel used in this work, J had a value of 16.
The effect of spatial uncertainty was included in the dose calcu-
lation by convolving the scatter kernel with a spatial uncertainty ker-
nel, and then convolving the result with the primary dose
distribution. The PDF of spatial uncertainty was speciﬁed as relative
probabilities, at intervals of 2 mm, in the anterior‐posterior, left‐right
and superior‐inferior directions, up to ±16 mm, giving 17 bins in
each direction. Each combination of position in the three directions
constituted a single point, uk, in the PDF kernel, and the product of
the individual histogram values for these positions yielded the corre-
sponding weight, ψk, of the kernel at that point. The motion kernel
therefore consisted of K = 17 × 17 × 17 = 4913 points and corre-
sponding weights.
The uncertainty kernel was then convolved with the scatter kernel.
This was a discrete convolution, such that s0m ¼ sj þ uk , σ0m ¼ σj  ψk ,
j = 1…J (= 16), k = 1…K (= 4913), m = 1…M (= 16 × 4913 = 78608).
For computational speed, the convolved kernel was resampled. A grid
of resolution 2 mm was cast over the kernel and the locations, s00n of
the grid voxels with the highest N = 4J (= 64) intensities, σ00n , were
selected as the new convolution kernel, with rescaling to ensure con-
servation of energy. Once the scatter kernel had been convolved with
the uncertainty kernel, the resulting kernel was convolved with the
primary dose distribution. This was carried out according to eq. (2),
but using the resampled scatter kernel:
Di rð Þ≈ ∑
N
n¼1
ϕ ri þ s00n
 
σ00n; i ¼ 1 . . . I; n ¼ 1 . . .N: (3)
Inverse planning then proceeded using this dose distribution at
each iteration. In principle, this could have led to the optimizer
attempting to compensate for the uncertainty distribution, but due
to the predominantly conformal arcs used, there was not much
scope allowed to the optimizer to do this. Consequently, no com-
pensation effects in the form of apertures boosting the periphery of
the ITV were observed in the completed plans. The main advantage
in using the dose calculation with uncertainty included for the opti-
mization as well as for ﬁnal dose calculation, was that it avoided a
sudden change in dose calculation algorithm at the end of the opti-
mization, which could have limited the quality of the results. For
consistency between patients, the same clinical objectives and con-
straints were used in all cases, as described in Table 1. The impor-
tance factors were relative, so that a given dosimetric change in a
structure with importance factor 10 had the same effect on the
course of the optimization as a dosimetric change 10× larger in a
structure with importance factor 1. In the case of probabilistic treat-
ment plans, the PTV objectives were reassigned to the ITV, with the
effect that the ITV root‐mean‐square (dose uniformity) objective
obtained a total importance of 20. This was to maintain the balance
of the optimization between the ITV and the organs at risk.
3 | RESULTS
Mean dose–volume histograms for the static plan and Gaussian
uncertainty plan are shown in Fig. 2 to illustrate the overall scenario.
For static planning (i.e., without considering uncertainty), the PTV is
prescribed such that PTV D95% = 54 Gy. Consequently, the ITV
receives a much higher dose, with ITV D95% ≈ 62 Gy and ITV
D50% ≈ 67 Gy. If, in contrast, the spatial uncertainty of the ITV is
taken into account during inverse planning and dose calculation, the
plan can be prescribed such that ITV D95% = 54 Gy. In this case the
ITV D50% ≈ 60 Gy, which is much closer to the intended dose. This
is important for the accuracy of radiation delivery to the target, but
it also beneﬁts the dose–volume histograms for the organs at risk.
Figure 3 examines this effect in more detail for each patient sep-
arately. In all cases, the ITV for static planning receives a much
higher dose than the intended prescription dose. When using a prob-
abilistic approach to prescribe to the ITV, the median ITV dose is
much closer to the prescribed dose. The choice of uncertainty distri-
bution can be seen from Fig. 3 to have a different impact on each
patient, but in general, the delta distribution gives a slightly lower
TAB L E 1 Clinical objectives and constraints.
Objective Structure Statistic Dose Importance









Minimize Lung‐ITV Vol irradiated to 11 Gy 4
Minimize Lung‐ITV Vol irradiated to 6 Gy 4
Minimize Heart Mean dose 1














Minimize Chest wall Maximum dose 1




Maximum dose 17 Gy N/A
awhen using spatial uncertainty.
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dose than the uniform distribution, and the Gaussian distribution
gives a slightly higher dose. Table 2 shows the full dose statistics for
all patients. Both the monitor units and ITV D50% are lower if the
prescription is to the ITV D95%. This table also indicates that the
choice of uncertainty distribution has little effect on the resulting
prescription.
The result of planning in the conventional manner but prescribing
to the ITV D95% is shown in Fig. 4. In all cases, when the plan is
recalculated including spatial uncertainty with a Gaussian distribu-
tion, the ITV D95% increases. The magnitude of this increase varies
from patient to patient. The statistics for this case are shown in
Table 3.
Results using ITV D100% (i.e., minimum dose to the ITV) instead
of ITV D95% are shown in Table 4 for the case of a Gaussian uncer-
tainty distribution. This approach results in a minimum dose to the
ITV which is higher than with prescription to the ITV D95%, but
F I G . 2 . Mean dose–volume histograms
for static plans and plans based on a
Gaussian distribution of spatial uncertainty.
The static plans are prescribed to the PTV
D95% and the probabilistic plans are
prescribed to ITV D95%.
F I G . 3 . Dose–volume histograms for
static and probabilistic plans. The static
plans are prescribed to the PTV D95% and
the probabilistic plans are prescribed to
ITV D95%.
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lower than when prescribing to the PTV D95%. Due to the slightly
greater inhomogeneity in ITV dose using this approach (see Fig. 3),
the ITV D50% is very similar to the static approach. The beneﬁt of
this prescription compared to prescribing to ITV D95% is that the ITV
receives full coverage with 54 Gy, but compared to the static
approach, there is little difference. In this case, the uncertainty
approach is explicitly modelling a situation similar to that which
results from using a PTV and a static approach. The greater dose
inhomogeneity in the ITV seen with the uncertainty approach
represents the blurring effect of the probability distribution of ITV
position.
4 | DISCUSSION
The recently published recommendations of ICRU for prescribing and
reporting of stereotactic treatments recognize that due to the higher
physical density of the ITV compared to the PTV, the ITV may receive
a higher dose than that prescribed to the PTV.5 Consequently, it is
recommended that the ITV D50% is reported. This study investigates a
further step, which is to prescribe to the ITV while accounting for the
uncertainty in its position. This results in an ITV dose which is much
closer to the intended prescription. These results are in accord with
those of Lacornerie et al.,29,30 who also show that the ITV D50% is a
key statistic for reporting delivered dose.
One possibility for implementation of this technique is to use the
spatial uncertainty concept for every patient. However, the results
of this study indicate that it may be possible to plan a static treat-
ment, without taking uncertainty into account, based on the PTV
but prescribed to the ITV. The resulting ITV D95% after recalculation
with an uncertainty distribution is not identical to that obtained
when planning and prescribing with the uncertainty distribution, but
is within 2%. This suggests that a simple re‐prescription is feasible,
which would enable a much wider implementation of the ﬁndings of
this work. In particular, a correction factor describing the impact of
the spatial uncertainty on the ITV D95% could be used.
In connection with such practical considerations, the study uses
a prescription to the ITV D95%, but other prescriptions are possible.
For example, prescription to the ITV D98% or D100% is also possible,
with appropriate adjustment of the prescribed dose, if coverage of
the ITV is of concern. Table 4 indicates that there is little difference
between prescribing to ITV D100% and the static approach in current
clinical practice. Similarly, isocentric prescriptions to the ICRU refer-
ence point have also been used in the literature.31 The results may
differ slightly for central tumors, due to the generally higher density
TAB L E 2 Median ± hemi‐range dose statistics for the ﬁve patients
in the study.
Treatment




3109 ± 485 2923 ± 604 2954 ± 463 3016 ± 683
ITV D100%
(Gy)
60.2 ± 2.8 50.8 ± 2.8 50.8 ± 1.3 49.2 ± 3.4
ITV D99%
(Gy)
61.0 ± 1.8 51.6 ± 3.5 52.4 ± 1.6 50.8 ± 3.8
ITV D95%
(Gy)
61.8 ± 2.9 54.0 ± 0.0 54.0 ± 0.0 54.0 ± 0.0
ITV D50%
(Gy)




– 0.88 ± 0.06 0.88 ± 0.04 0.88 ± 0.06
ITV mean
dose (Gy)
66.8 ± 4.0 59.2 ± 0.5 58.5 ± 1.8 60.4 ± 1.4
F I G . 4 . Dose–volume histograms for static plans prescribed to ITV
D95% and then recalculated using a Gaussian probability distribution.
TAB L E 3 Median ± hemi‐range dose statistics for a static plan
prescribed to ITV D95% and evaluated using a Gaussian uncertainty
distribution.
Treatment plan Gaussian Recalculated Gaussian
Fraction monitor units 3016 ± 683 2689 ± 450
ITV D100% (Gy) 49.2 ± 3.4 53.2 ± 0.9
ITV D99% (Gy) 50.8 ± 3.8 53.8 ± 0.6
ITV D95% (Gy) 54.0 ± 0.0 54.8 ± 0.5
ITV D50% (Gy) 60.6 ± 1.7 58.0 ± 1.3
ITV D50% w.r.t. static 0.88 ± 0.06 0.87 ± 0.04
ITV mean dose (Gy) 60.4 ± 1.4 58.4 ± 1.1
TAB L E 4 Median ± hemi‐range dose statistics for a plan prescribed
to ITV D100% using a Gaussian uncertainty distribution.
Treatment plan Static Gaussian
Fraction monitor units 3109 ± 485 4047 ± 745
ITV D100% (Gy) 60.2 ± 2.8 54.0 ± 0.0
ITV D99% (Gy) 61.0 ± 1.8 55.2 ± 2.0
ITV D95% (Gy) 61.8 ± 2.9 59.8 ± 0.9
ITV D50% (Gy) 66.6 ± 4.2 67.6 ± 1.2
ITV D50% w.r.t. static – 1.01 ± 0.07
ITV mean dose (Gy) 66.8 ± 4.0 67.4 ± 0.9
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of the surrounding tissue in the mediastinal region, but this effect is
not expected to alter the conclusion that prescription to the ITV is
important.
This work uses a PDF of position to calculate the expected dose
distribution in the presence of spatial uncertainty. This is more efﬁ-
cient to calculate and provides a more realistic result than the isocen-
ter shift method, which has also been used in the context of lung
radiotherapy.32,33 The approach used in this study is to retain the
normal calculation of primary ﬂuence but then to use the PDF to
model local spatial uncertainty. The uncertainty is considered to be in
the ITV position, but the convolution approach implicitly applies the
uncertainty distribution throughout the patient, so that other struc-
tures are also affected. The magnitude of this effect on other organs
is small compared to the change in normal tissue dose shown in
Fig. 2 due to change in prescription. The use of a PDF is also closely
allied to the ﬁeld of robust optimization, which has been widely used
in proton therapy,34,35 where particle range is of particular impor-
tance. In this study, the optimizer has only been given limited scope
to adapt the treatment plan in compensation for the expected uncer-
tainty. This is due to the predominantly conformal arc.
The work reported in this paper does not address the question
of a systematic error in positioning. The uncertainty distributions
used are all symmetric about the origin, so assume that a shift is as
likely to occur in one direction as the opposite direction. In reality, a
contouring error or spatial registration error when registering cone‐
beam CT images may result in a shift rather than a symmetrical
blurring of the dose distribution.32 Use of a worst‐case (minimax)
algorithm may enable this to be further investigated.36–38 This type
of algorithm focuses on the impact of the worst‐case scenario with
respect to spatial uncertainty, and can therefore better handle a sys-
tematic error. Furthermore, although the dose calculation algorithm
used in this study is known to be compatible with current commer-
cial convolution algorithms, the results should be validated more
thoroughly with a clinical dose calculation algorithm before imple-
mentation of the outcome. The dose calculation algorithm described
in this study uses a spatially invariant scatter kernel [see eq. (1)],
which is known to be less accurate in lung than a full convolution–
superposition approach with a variant scatter kernel. This limitation
is expected to have a small impact on the results of the study, so
validation in a commercial treatment planning system is desirable.
This study shows that the difference between prescription to
the PTV D95% and ITV D95% is of the order of 15%, so that imple-
mentation of the results should be carried out with caution, and
preferably with the consensus of the international radiation therapy
community. A change in this magnitude has already been success-
fully effected in the context of RTOG 0236 and RTOG 0813, where
60 Gy in 3 fractions without heterogeneity correction is taken as
being equivalent to 54 Gy in 3 fractions with heterogeneity correc-
tions.4 Although the treatments are ablative in intent, so that it may
be argued that the minimum dose is the most important, it is
nonetheless important that delivered doses are accurately pre-
scribed and reported. This study proposes a method of taking a fur-
ther step toward this goal.
5 | CONCLUSION
This study shows that using a robust probabilistic approach to plan-
ning SBRT lung treatments, and prescribing to the ITV, results in the
ITV receiving a dose closer to the intended prescription than when
using a static approach and prescription to the PTV. The exact form
of the uncertainty distribution used in this approach is not found to
be critical. Planning the treatment with a static approach and pre-
scribing to the ITV gives a result which is very close to that obtained
with a probabilistic approach.
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